LMO2-containing complexes in leukemia and blood cell development

含有 LMO2 的复合物在白血病和血细胞发育中的作用

• 批准号: nhmrc : 1004651
• 负责人: E/Pr Jules Guss
• 金额: $ 53.59万
• 依托单位: The University of Sydney
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2011
• 资助国家: 澳大利亚
• 起止时间: 2011-01-01 至 2014-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/lmo2-containing-complexes-cell-development/109059
• 关键词: LMO2; containing; complexes; leukemia; blood

Childhood T-cell leukemias have a poor prognosis for recovery. We are determining, with atomic level precision, how the proteins Lmo2 (also linked to prostate and other cancers) and Tal1, and their binding partners contribute to both normal blood cell development and T-cell leukemia. With this information we are developing reagents that can be used to disrupt disease-causing complexes, and which will lead towards the development of new, specific, therapeutics for leukemias and other cancers.

儿童T细胞白血病的预后很差。我们正在以原子水平的精度确定蛋白质Lmo2（也与前列腺癌和其他癌症有关）和Tal 1及其结合伴侣如何促进正常血细胞发育和T细胞白血病。有了这些信息，我们正在开发可用于破坏致病复合物的试剂，这将导致白血病和其他癌症的新的、特异性的治疗方法的开发。